These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18668567)

  • 1. Rituximab treatment in children: comment on the review by Looney et al.
    Bader-Meunier B
    Arthritis Rheum; 2008 Aug; 58(8):2583; author reply 2583-4. PubMed ID: 18668567
    [No Abstract]   [Full Text] [Related]  

  • 2. A review of the current use of rituximab in autoimmune diseases.
    Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
    Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of Evans syndrome combined with systemic lupus erythematosus successfully treated with rituximab.
    Kittaka K; Dobashi H; Baba N; Iseki K; Kameda T; Susaki K; Kitanaka A; Kubota Y; Ishida T
    Scand J Rheumatol; 2008; 37(5):390-3. PubMed ID: 18609263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of rituximab on immunocompetency in patients with autoimmune disease.
    Looney RJ; Srinivasan R; Calabrese LH
    Arthritis Rheum; 2008 Jan; 58(1):5-14. PubMed ID: 18163518
    [No Abstract]   [Full Text] [Related]  

  • 5. Short-term effects of rituximab on flow-mediated dilatation may be mediated by intravenous glucocorticoids: comment on the article by Gonzalez-Juanatey et al.
    Sandoo A; Toms T; Zanten JV; Carroll D; Kitas G
    Arthritis Rheum; 2009 Jun; 61(6):854-5; author reply 855-6. PubMed ID: 19479694
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome.
    Pranzatelli MR; Tate ED; Travelstead AL; Longee D
    Pediatrics; 2005 Jan; 115(1):e115-9. PubMed ID: 15601813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mAbs in nonlupus autoimmune rheumatic disease.
    Whelan BR; Isenberg DA
    Curr Opin Hematol; 2009 Jul; 16(4):280-4. PubMed ID: 19444098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome.
    Leen WG; Weemaes CM; Verbeek MM; Willemsen MA; Rotteveel JJ
    Pediatr Neurol; 2008 Sep; 39(3):213-7. PubMed ID: 18725071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis.
    Blank N; Max R; Schiller M; Briem S; Lorenz HM
    Rheumatology (Oxford); 2009 Apr; 48(4):440-1. PubMed ID: 19153143
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 11. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.
    Bayry J; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Nat Clin Pract Rheumatol; 2007 May; 3(5):262-72. PubMed ID: 17471245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted ITP strategies: do they elucidate the biology of ITP and related disorders?
    Bennett CM; de Jong JL; Neufeld EJ
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):706-9. PubMed ID: 16933263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenetic mechanisms, new drugs, and old problems in idiopathic recurrent pericarditis: comment on the article by Picco et al.
    Brucato A; Imazio M; Spodick D; Adler Y
    Arthritis Rheum; 2009 Aug; 60(8):2543; author reply 2543-4. PubMed ID: 19644862
    [No Abstract]   [Full Text] [Related]  

  • 14. Acquired immune cytopenias post-cardiac transplantation respond to rituximab.
    Tubman VN; Smoot L; Heeney MM
    Pediatr Blood Cancer; 2007 Mar; 48(3):339-44. PubMed ID: 16435382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: comment on the article by Sfikakis et al.
    van Vollenhoven R; Gunnarsson I
    Arthritis Rheum; 2005 Dec; 52(12):4050-1; author reply 4051-2. PubMed ID: 16320358
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.
    Narváez J; Díaz-Torné C; Juanola X; Geli C; Llobet JM; Nolla JM; Díaz-López C
    Ann Rheum Dis; 2009 Apr; 68(4):607-8. PubMed ID: 19286909
    [No Abstract]   [Full Text] [Related]  

  • 17. [Use of intravenous immunoglobulin preparations (IVIG) in treatment of primary cell immunodeficiencies].
    Siwińska-Gołebiowska H; Czerwińska-Kartowicz I; Markiewicz K
    Postepy Hig Med Dosw; 2002; 56 Suppl():33-40. PubMed ID: 12661412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell depletion in autoimmune diseases. Advances in autoimmunity.
    Guzman Moreno R
    Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
    Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
    Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on: a case of Raynaud's phenomenon in mixed connective tissue disease responding to Rituximab therapy response.
    Dunkley L; Green M; Gough A
    Rheumatology (Oxford); 2007 Oct; 46(10):1628-9. PubMed ID: 17766999
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.